Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 2;7:336. doi: 10.1186/s40425-019-0818-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Timeline of the patient’s clinical, therapeutic, and radiological course. The 11 cycles of nivolumab administration and its related onset and resolution of CNS demyelinating lesions are highlighted in red. A time reference has been included, with Day 0 referring to the day of onset of nivolumab treatment. Abbreviations: LN: lymph node; C: cycle; SRS: stereotactic radiosurgery; Dx: diagnosis; TT: treatment; DEX: dexamethasone; PD: progressive disease; PR: partial response; MRI: magnetic resonance imaging; CT: computed tomography; CNS: central nervous system. *5 mg/kg; **1 mg i.d. for 7 days, and 5.25 mg tapered over 14 days